Application of maltobionic acid and its composition in bacteriostasis, anti-inflammation, skin barrier repair and acne improvement products

Abstract

This invention relates to the field of cosmetics, specifically disclosing the application of maltodextrin and its compositions in antibacterial, anti-inflammatory, skin barrier repair, and acne-improving products. The maltodextrin disclosed in this invention can significantly inhibit Propionibacterium acnes. Furthermore, by combining the multiple effects of maltodextrin, or by using maltodextrin in combination with adjuvants, significant improvement in acne conditions can be achieved.

Description

Technical Field

[0001] This invention relates to novel applications of maltodextrin and its compositions. Specifically, it relates to the application of maltodextrin and its compositions in products that inhibit bacteria, reduce inflammation, repair the skin barrier, and improve acne, including effectively removing acne, eliminating acne, inhibiting acne growth, and inhibiting acne recurrence. Background Technology

[0002] Acne has become a prevalent skin problem worldwide, affecting a wide range of people across multiple age groups. It manifests not only as recurring pimples, papules, and nodules, but is also frequently accompanied by post-inflammatory erythema, pigmentation, and even scarring, significantly impacting patients' psychological well-being, social interactions, and quality of life. Therefore, finding safe, effective, and long-term skincare solutions has become a core demand for consumers struggling with acne.

[0003] Besides normal physiological skin metabolism, common causes of acne include: excessive sebum secretion; abnormal follicular keratosis; proliferation of Propionibacterium acnes; endocrine disorders such as changes in androgen levels and hormonal fluctuations during menstruation; inflammatory response; improper diet; stress and irregular work and rest; genetic factors; and improper skin care or use of cosmetics.

[0004] Traditional acne treatments often only address the symptoms, not the root cause. Specifically, most traditional acne products only reduce inflammation, redness, and pustules, targeting mature pimples. However, the root causes of acne are excessive sebum production, clogged follicles, proliferation of Propionibacterium acnes, and latent inflammation. These products completely ignore these core issues, essentially extinguishing the surface fire without cutting off the fuel. Closed comedones and micro-comedones continue to form, leading to new pimples appearing quickly, resulting in a perpetually reactive approach to acne treatment. Research shows that acne-prone skin is essentially a predisposed skin condition: oily, with a fragile skin barrier, imbalanced gut microbiota, and easily clogged follicles. Traditional products only eliminate the acne without controlling oil production, unclogging follicles, repairing the skin barrier, or regulating gut microbiota, leaving the skin with the predisposing conditions for acne. It's like treating only the symptoms without addressing the underlying cause, thus failing to inhibit acne growth, and resulting in recurring breakouts. In other words, traditional acne treatments don't stabilize or consolidate the skin's condition. Stopping medication / products as soon as acne clears leaves the skin without any defense against recurrence, making it susceptible to rebound from even the slightest trigger. The end result is a vicious cycle of treatment-relapse-treatment. Without controlling the acne development cycle, repeated inflammation, redness, and rupture easily leave pigmented acne scars and pitted acne pits. Furthermore, simply reducing inflammation without addressing underlying inflammation can leave residual inflammation that continues to irritate the skin, further triggering new acne and creating a vicious cycle. Additionally, traditional products are only effective on mature, red, swollen pimples and pustular acne; they are completely ineffective against microcomedones and closed comedones—the very seeds of acne growth. Without early intervention and suppression of early skin lesions, it's impossible to truly stop acne growth, let alone prevent it.

[0005] For example, mainstream active ingredients on the market typically target different areas. Retinoids (such as tazarotene and adapalene) are the gold standard for regulating keratinocyte differentiation and anti-keratinization, but they are highly irritating and easily cause dryness and peeling. Benzoyl peroxide rapidly inhibits infection with its potent antibacterial and mild exfoliating effects, but it significantly damages the skin barrier and may cause contact dermatitis. Salicylic acid, as a lipid-soluble β-hydroxy acid, can unclog hair follicles and reduce inflammation, but for consumers with dry or sensitive skin, it can easily cause skin stinging and peeling caused by "acid peeling." In addition, auxiliary ingredients such as zinc salts, niacinamide, and tea tree oil mainly work by regulating sebum, anti-inflammatory soothing, or assisting in antibacterial effects, and are often used as part of compound formulations to enhance overall efficacy and reduce irritation. However, these formulations often struggle to balance efficacy, tolerability, and prevention of recurrence, necessitating the development of newer, gentler ingredients that can work synergistically across multiple pathways.

[0006] Maltodextrin is a novel cosmetic ingredient whose application value and potential have not yet been fully explored. Currently, in the international market, this ingredient is mainly used as an additive to help improve skin condition, and related literature reports mostly focus on its effects on skin rejuvenation, anti-photoaging, and moisturizing. Summary of the Invention

[0007] This invention aims to explore the new functions of maltodextrin, systematically verifying that maltodextrin has a significant inhibitory effect on Propionibacterium acnes, a highly efficient skin barrier repair ability, and points out that it has outstanding comprehensive anti-acne potential.

[0008] In one study of this invention, the novel functions of maltodextrin were explored in depth. Based on the core principle that maltodextrin effectively inhibits Propionibacterium acnes, it also has the functions of multi-pathway synergistic improvement and active barrier repair, as detailed below: This ingredient directly inhibits the proliferation of Propionibacterium acnes, intervening in the formation of acne at its source; This ingredient gently promotes the metabolism of dead skin cells, unclogs pores, comprehensively improves the appearance of skin damage, fades acne scars, and enhances skin smoothness. This ingredient also simultaneously achieves antioxidant and anti-glycation functions, thereby reducing skin inflammation and preventing and fading post-inflammatory hyperpigmentation by inhibiting melanin production; This ingredient enhances the skin barrier function and moisturizing ability by promoting the production of desmosomes and filaggrin, reducing transepidermal water loss, improving the skin from the source, and eliminating the breeding ground for acne recurrence.

[0009] This ingredient effectively repairs acne-prone skin damage and avoids side effects such as dryness, peeling, irritation, and allergies that may be caused by other active ingredients, achieving the effect of simultaneously improving acne and its accompanying symptoms on multiple targets.

[0010] In another study of this invention, a composition for improving acne is provided, wherein maltodextrin is present in the composition at a mass percentage of 0.0001-99.9%. It has the effects of preventing acne formation, alleviating existing acne symptoms, and improving the skin appearance after acne has subsided.

[0011] The composition contains cosmetically acceptable active ingredients, cosmetically acceptable diluents, or carriers.

[0012] The above-mentioned acceptable active ingredients in cosmetics are selected from sebum-regulating active substances, antibacterial active substances, oil-controlling active substances, pore-cleansing agents, antioxidants, free radical scavengers, anti-inflammatory agents, tocopherol-like substances, retinol-like substances, soothing active substances, barrier-repairing active substances, blood circulation-promoting active substances, exfoliating active substances, anti-allergic active substances, redness-reducing active substances, whitening agents, moisturizers, cooling agents, abrasives, surfactants, emollients, skin conditioning agents, penetration enhancers, astringents, retinol, hydroxypinazone retinate, retinaldehyde, retinaldehyde retinate, pyridoxine tri-hexyldecanoate, glutamine ethyl imidazole, hydroxypropyl tetrahydropyranotriol, ergothioneine, and tetrahydromethylpyrimidine carboxylic acid. Ascorbic acid tetraisopalmitate, tetrahexyldecyl ascorbate, 3-o-ethyl ascorbic acid, ceramide NP, hydroxyphenylpropionamide benzoic acid, acetylhydroxyproline, tocopherol nicotinate, ethyl diiminomethyl guaiacol manganese chloride, quaternary ammonium salt-73, arginine / lysine peptide, myristyl nicotinate, dipalmitoyl hydroxyproline, pinanediol, camphene diol, pepper leaf / root / stem extract, oat extract, dipeptide-15, bis-diethoxydiethylene cyclohexane 1,4-dicarboxylic acid ester, dihydromyricetin, tetrahydromagnoliol, nicotinamide adenine dinucleotide, acetylglutathione, panthioethylamine, plant exosomes, mesenchymal stem cell exosomes, and combinations thereof.

[0013] The acceptable diluents or carriers for the above cosmetics are selected from: (Alkane)diols or triols having 3-10 carbon atoms, preferably selected from glycerol, 1,2-propanediol, 1,3-propanediol, 2-methylpropane-1,3-diol, 1,2-butanediol, 1,3-butanediol, 1,2-pentanediol, 1,3-pentanediol, 1,5-pentanediol, 2,4-pentanediol, 2-methylpentane-2,4-diol, 1,2-hexanediol, 1,6-hexanediol, 1,2-octanediol, dipropylene glycol, preferably 1,2-butanediol, 1,2-pentanediol and / or dipropylene glycol, and / or Esters having 6-36 carbon atoms, preferably monoesters, diesters, or triesters, and preferably selected from diethyl phthalate, diethylhexyl 2,6-naphthalenedicarboxylate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 3,5,5-trimethylhexanoate, and 2-ethylhexyl isononanoate. 2-Ethylhexyl 3,5,5-Trimethylhexanoate, 2-Ethylhexyl 2-Ethylhexanoate, 2-Ethylhexyl palmitate, 2-Ethylhexyl laurate, 2-Hexyldecyl stearate, Cetearyl ethylhexanoate, Stearyl heptanoate, Stearyl octanoate, 2-Octyldodecyl palmitate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, 2-Ethylhexyl isostearate, Isotridecyl isononanoate, 2-Ethylhexyl cocoate, C benzoate 12 -15-alkyl esters, cetyl palmitate, triethyl citrate, triacetyl citrate, benzyl benzoate, benzyl acetate, vegetable oils (preferably olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil) and triglycerides, especially glyceryl stearate, triisononanoate, glyceryl laurate, or triglycerides having the same or different CC fatty acid groups (so-called medium-chain triglycerides, especially caprylic / capric triglycerides such as caprylic triglyceride, capric triglyceride), and / or Branched and unbranched alkyl or alkenyl alcohols, preferably selected from decanol, decenol, octanol, octenol, dodecanool, dodecadienol, octadienol, decadienol, oleyl alcohol, castor oil alcohol, garnet alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, linoleyl alcohol, linolenic acid alcohol, hexyldecyl alcohol, octyldodecyl alcohol (especially 2-octyl-1-dodecyl alcohol), cetearyl alcohol and behenyl alcohol, and / or Branched and unbranched hydrocarbons and waxes, cyclic or linear silicone oils and dialkyl ethers having 6-24 carbon atoms, preferably selected from jojoba oil, isoeicosane, dioctyl ether, mineral oil, petrolatum, squalane, squalene, cyclopolymethylsiloxane, decamethylcyclopentasiloxane, undecylmethylcyclotrisiloxane, polydimethylsiloxane and polymethylphenylsiloxane.

[0014] This acne-improving composition may be in any form, including solutions, emulsions, suspensions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, and sprays.

[0015] It can be used as a wash-off cosmetic or a leave-on cosmetic. Attached Figure Description

[0016] Figure 1 To assess the effect of maltodextrin on promoting the production of the desquamation-related protease KLK7 in this embodiment, statistical analysis was performed using the t-test method. Compared with group BC, significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.15 was indicated by **.

[0017] Figure 2 To assess the effect of maltodextrin in promoting Caspase-14 production in this embodiment, statistical analysis was performed using the t-test method. Compared with group BC, significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.15 was indicated by **.

[0018] Figure 3 To assess the effect of maltodextrin on desmosome core protein (DSC1) production in this embodiment, statistical analysis was performed using the t-test method. Significance compared to the BC group was indicated by *, P-value < 0.05 was indicated as *, and P-value < 0.15 was indicated as **.

[0019] Figure 4 To assess the effect of maltodextrin on the production of desmosome core glycoprotein (DSG1) in this embodiment, statistical analysis was performed using the t-test method. Compared with the BC group, significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.15 was indicated by **.

[0020] Figure 5 To assess the effect of the 4% maltodextrin essence in reducing transepidermal water loss (TEWL) in this embodiment, statistical analysis was performed using the t-test method. Significance compared to group BC was indicated by *, P-value < 0.05 was indicated as *, and P-value < 0.15 was indicated as **. Detailed Implementation

[0021] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, and not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0022] Example 1. In vitro test of the effect of maltodextrin on inhibiting Propionibacterium acnes.

[0023] To determine whether maltodextrin possesses the potential to treat acne, its ability to inhibit the growth and reproduction of Propionibacterium acnes was tested in this embodiment.

[0024] The strain used in the test was Propionibacterium acnes (ATCC 6919) third generation, provided by Guangdong Boxi Biotechnology Co., Ltd.

[0025] The active ingredient sample used in the test was maltodextrin, marketed under the brand name Anallerg®-NFA, and provided by Shanghai Keqin Technology Co., Ltd.

[0026] The test was divided into a growth control group, a blank control group, and a sample group.

[0027] Test method: Add the samples to autoclaved agar medium at 40℃~50℃, at concentrations of 0.032% (m / v), 0.16% (m / v), 0.8% (m / v), 1.5% (m / v), 2% (m / v), 3% (m / v), 4% (m / v), and 20% (m / v). After the agar and samples are thoroughly mixed, pour into Petri dishes. Prepare a bacterial suspension with a concentration of 1×10⁻⁶. 8 CFU / mL ~2×10 8 CFU / mL was used as the initial inoculum. The initial inoculum was diluted 1:10 and set aside. Using a sterile inoculation loop, 1 μL of the bacterial suspension was added to the growth control group without sample, the surface of a TSA agar medium plate containing sample (from low to high concentration), and the blank control group, respectively. The final inoculum volume was 1×10⁻⁶. 4 CFU / point. Incubate anaerobically at 36°C for 72 hours.

[0028] Evaluation of antibacterial effect: Place the petri dish on a black, non-reflective background and read the results. The minimum concentration at which bacterial growth is visibly inhibited is defined as the MIC. If no colony growth occurs, the sample concentration has an antibacterial effect against Propionibacterium acnes; if colony growth occurs, the sample concentration has no antibacterial effect against Propionibacterium acnes.

[0029] Results: As shown in the table below, based on Propionibacterium acnes, sample Anallerg ® - The minimum inhibitory concentration (MIC) of NFA in the concentration range of 0.032%-20% (m / v) is 1.5% (m / v).

[0030] Example 2. In vitro test of the effect of maltodextrin on promoting the production of the desquamation-related protease KLK7.

[0031] KLK7 (kallikrein-associated peptidase 7) is a key protease in the normal shedding and metabolism of the stratum corneum, primarily responsible for degrading the connective proteins between keratinocytes, allowing aged keratinocytes to shed naturally. Therefore, this embodiment verifies whether the test substance can upregulate KLK7 gene expression and the level of expression to determine its ability to accelerate stratum corneum renewal and improve keratin buildup, thereby evaluating its potential to improve rough, dull, and abnormally keratinized skin. Furthermore, it also evaluates its potential to unclog pores and reduce closed comedones and acne caused by dead skin cells clogging the pores.

[0032] The test was based on a 3D epidermal skin model (Epikutis®), provided by Guangdong Boxi Biotechnology Co., Ltd.

[0033] The active ingredient sample used in the test was maltodextrin, marketed under the brand name Anallerg®-NFA, and provided by Shanghai Keqin Technology Co., Ltd.

[0034] The test consisted of a blank control (BC) and a sample group. The sample group consisted of maltodextrin solution (maltodextrin concentrations of 2%, 4%, and 6%, respectively).

[0035] Stimulation and drug administration: According to the test groups, the models were transferred to 6-well plates (pre-added with 0.9 mL of EpiGrowth medium) and the test group numbers were labeled on the 6-well plates. For the sample groups, the working solution was evenly distributed on the model surface and incubated in a CO2 incubator (37℃, 5% CO2) for 24 h. After incubation, residual test samples were washed with sterile PBS solution, and residual liquid was wiped away with sterile cotton swabs.

[0036] Immunofluorescence assay: The model used for detection was circumcised and fixed with 4% paraformaldehyde. After 24 hours of fixation, immunofluorescence was performed, and images were taken and analyzed under a microscope.

[0037] Result: As Figure 1 Maltodextrin, 2%, 4%, and 6% significantly promoted the expression of KLK7 protease, with upregulation rates of 115%, 167%, and 239%, respectively.

[0038] Example 3. In vitro test of the effect of maltodextrin on promoting the production of cysteine-aspartic acid specific protease (Caspase-14).

[0039] Caspase-14 is a key protease in terminal differentiation of keratinocytes, formation of the keratinized capsule, and maturation of the skin barrier, and is closely related to skin hydration, barrier integrity, and normal stratum corneum metabolism. In vitro testing of the regulatory effect of maltodextrin on caspase-14 can, on the one hand, verify its molecular mechanism of action on skin keratinocytes. On the other hand, it can evaluate the potential of maltodextrin to promote keratin maturation, strengthen the skin barrier, and reduce transepidermal water loss. Furthermore, it can estimate the potential of maltodextrin to promote normal keratin differentiation, improve keratin buildup, roughness, dullness, and improve skin texture.

[0040] The test was based on a 3D epidermal skin model (Epikutis®), provided by Guangdong Boxi Biotechnology Co., Ltd.

[0041] The active ingredient sample used in the test was maltodextrin, marketed under the brand name Anallerg®-NFA, and provided by Shanghai Keqin Technology Co., Ltd.

[0042] The test consisted of a blank control (BC) and a sample group. The sample group consisted of maltodextrin solution (maltodextrin concentrations of 2%, 4%, and 6%, respectively).

[0043] Stimulation and drug administration: According to the test groups, the models were transferred to 6-well plates (pre-added with 0.9 mL of EpiGrowth medium) and the test group numbers were labeled on the 6-well plates. For the sample groups, the working solution was evenly distributed on the model surface and incubated in a CO2 incubator (37℃, 5% CO2) for 24 h. After incubation, residual test samples were washed with sterile PBS solution, and residual liquid was wiped away with sterile cotton swabs.

[0044] Immunofluorescence assay: The model used for detection was circumcised and fixed with 4% paraformaldehyde. After 24 hours of fixation, immunofluorescence was performed, and images were taken and analyzed under a microscope.

[0045] Result: As Figure 2 4% and 6% maltodextrin significantly promoted the expression of Caspase-14, with upregulation rates of 130% and 279%, respectively.

[0046] Example 4. In vitro test of the effect of maltodextrin on promoting the production of desmosome coreglucan (DSC1) and desmosome core glycoprotein (DSG1).

[0047] DSC1 and DSG1 are core components of the desmosome structure between epidermal keratinocytes, responsible for maintaining cell adhesion, stratum corneum integrity, and skin barrier function. In vitro detection of the promoting effect of maltodextrin on the expression of these two proteins can verify the regulatory role of maltodextrin in epidermal cell junction structure, clarify whether maltodextrin can upregulate the gene expression or protein synthesis levels of DSC1 and DSG1, and elucidate its mechanism of influence on epidermal desmosome structure at the molecular level. Furthermore, the effects of maltodextrin on improving skin texture, desquamation, and stratum corneum stability can also be evaluated.

[0048] The test was based on a 3D epidermal skin model (Epikutis®), provided by Guangdong Boxi Biotechnology Co., Ltd.

[0049] The active ingredient sample used in the test was maltodextrin, marketed under the brand name Anallerg. ® -NFA, provided by Shanghai Keqin Technology Co., Ltd.

[0050] The test consisted of a blank control (BC) and a sample group. The sample group consisted of maltodextrin solution (maltodextrin concentrations of 2%, 4%, and 6%, respectively).

[0051] Stimulation and drug administration: According to the test groups, the models were transferred to 6-well plates (pre-added with 0.9 mL of EpiGrowth medium) and the test group numbers were labeled on the 6-well plates. For the sample groups, the working solution was evenly distributed on the model surface and incubated in a CO2 incubator (37℃, 5% CO2) for 24 h. After incubation, residual test samples were washed with sterile PBS solution, and residual liquid was wiped away with sterile cotton swabs.

[0052] Immunofluorescence assay: The model used for detection was circumcised and fixed with 4% paraformaldehyde. After 24 hours of fixation, immunofluorescence was performed, and images were taken and analyzed under a microscope.

[0053] Result: As Figure 3 Maltose 2%, 4%, and 6% significantly promoted the expression of desmosome core glue protein (DSC1), with upregulation rates of 666%, 1104%, and 170%, respectively. Figure 4 Maltodextrin at concentrations of 2%, 4%, and 6% significantly promoted the expression of desmosome core glycoprotein (DSG1), with upregulation rates of 37%, 87%, and 96%, respectively.

[0054] Example 5. Human efficacy evaluation test of the effect of 4% maltodextrin (Anallerg®-NFA) serum in reducing transepidermal water loss (TEWL).

[0055] Testing Methods: The test employed pre- and post-treatment controls and parallel controls, selecting 31 subjects. Each subject used the sample twice daily, morning and evening, and a transdermal water loss (TEWL) meter was used to take photos and measure the TEWL at designated follow-up time points. The repair efficacy of the sample was evaluated by statistically analyzing the initial values ​​before sample use and the TEWL values ​​after 4 weeks of sample use.

[0056] The test consisted of a control area and a test area. The control area was coated with a base serum (glycerin 15.00, xanthan gum 0.50, urea 20.00, triacetin 4.00, hydroxamic acid / 1,2-hexanediol / 1,3-propanediol 0.80, arginine 2.00, 1% kava pepper extract 0.50, rose water to 100%). The test area was coated with a serum containing 4% Anallerg®-NFA. The only difference between the two serums was the addition of 4% Anallerg®-NFA as the active ingredient. Both serums were provided by Shanghai Keqin Technology Co., Ltd.

[0057] Results Analysis: Descriptive statistics were performed on the measured values ​​of each test area before and after the initial comparison. The initial values ​​of each test area were calculated and the measured values ​​at other time points were compared. The differences between the measured values ​​at different time points and the initial values ​​were statistically analyzed. Parallel comparative descriptive statistics were also performed on the measured values ​​of each test area. The differences between the initial values ​​of each test area and the measured values ​​at other time points were calculated. These differences were then used to statistically analyze the differences between the sample group and the control group at different time points. Two-tailed tests were used for all statistical methods, with a significance level of α=0.05.

[0058] Result: As Figure 5 After 4 weeks of continuous use of the samples (control group used matrix essence, sample group used 4% NFA essence), the transdermal water loss (TEWL) value in the test area was reduced by 28.64%.

[0059] Example 6. Composition for improving acne The mass percentage of maltodextrin in the composition is 0.0001-99.9%.

[0060] The composition contains cosmetically acceptable active ingredients, cosmetically acceptable diluents, or carriers.

[0061] The above-mentioned acceptable active ingredients in cosmetics are selected from sebum-regulating active substances, antibacterial active substances, oil-controlling active substances, pore-cleansing agents, antioxidants, free radical scavengers, anti-inflammatory agents, tocopherol-like substances, retinol-like substances, soothing active substances, barrier-repairing active substances, blood circulation-promoting active substances, exfoliating active substances, anti-allergic active substances, redness-reducing active substances, whitening agents, moisturizers, cooling agents, abrasives, surfactants, emollients, skin conditioning agents, penetration enhancers, astringents, retinol, hydroxypinazone retinate, retinaldehyde, retinaldehyde retinate, pyridoxine tri-hexyldecanoate, glutamine ethyl imidazole, hydroxypropyl tetrahydropyranotriol, ergothioneine, and tetrahydromethylpyrimidine carboxylic acid. Ascorbic acid tetraisopalmitate, tetrahexyldecyl ascorbate, 3-o-ethyl ascorbic acid, ceramide NP, hydroxyphenylpropionamide benzoic acid, acetylhydroxyproline, tocopherol nicotinate, ethyl diiminomethyl guaiacol manganese chloride, quaternary ammonium salt-73, arginine / lysine peptide, myristyl nicotinate, dipalmitoyl hydroxyproline, pinanediol, camphene diol, pepper leaf / root / stem extract, oat extract, dipeptide-15, bis-diethoxydiethylene cyclohexane 1,4-dicarboxylic acid ester, dihydromyricetin, tetrahydromagnoliol, nicotinamide adenine dinucleotide, acetylglutathione, panthioethylamine, plant exosomes, mesenchymal stem cell exosomes, and combinations thereof.

[0062] The acceptable diluents or carriers for the above cosmetics are selected from: (Alkane)diols or triols having 3-10 carbon atoms, preferably selected from glycerol, 1,2-propanediol, 1,3-propanediol, 2-methylpropane-1,3-diol, 1,2-butanediol, 1,3-butanediol, 1,2-pentanediol, 1,3-pentanediol, 1,5-pentanediol, 2,4-pentanediol, 2-methylpentane-2,4-diol, 1,2-hexanediol, 1,6-hexanediol, 1,2-octanediol, dipropylene glycol, preferably 1,2-butanediol, 1,2-pentanediol and / or dipropylene glycol, and / or Esters having 6-36 carbon atoms, preferably monoesters, diesters, or triesters, and preferably selected from diethyl phthalate, diethylhexyl 2,6-naphthalenedicarboxylate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 3,5,5-trimethylhexanoate, and 2-ethylhexyl isononanoate. 2-Ethylhexyl 3,5,5-Trimethylhexanoate, 2-Ethylhexyl 2-Ethylhexanoate, 2-Ethylhexyl palmitate, 2-Ethylhexyl laurate, 2-Hexyldecyl stearate, Cetearyl ethylhexanoate, Stearyl heptanoate, Stearyl octanoate, 2-Octyldodecyl palmitate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, 2-Ethylhexyl isostearate, Isotridecyl isononanoate, 2-Ethylhexyl cocoate, C benzoate 12 -15-alkyl esters, cetyl palmitate, triethyl citrate, triacetyl citrate, benzyl benzoate, benzyl acetate, vegetable oils (preferably olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil) and triglycerides, especially glyceryl stearate, triisononanoate, glyceryl laurate, or triglycerides having the same or different CC fatty acid groups (so-called medium-chain triglycerides, especially caprylic / capric triglycerides such as caprylic triglyceride, capric triglyceride), and / or Branched and unbranched alkyl or alkenyl alcohols, preferably selected from decanol, decenol, octanol, octenol, dodecanool, dodecadienol, octadienol, decadienol, oleyl alcohol, castor oil alcohol, garnet alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, linoleyl alcohol, linolenic acid alcohol, hexyldecyl alcohol, octyldodecyl alcohol (especially 2-octyl-1-dodecyl alcohol), cetearyl alcohol and behenyl alcohol, and / or Branched and unbranched hydrocarbons and waxes, cyclic or linear silicone oils and dialkyl ethers having 6-24 carbon atoms, preferably selected from jojoba oil, isoeicosane, dioctyl ether, mineral oil, petrolatum, squalane, squalene, cyclopolymethylsiloxane, decamethylcyclopentasiloxane, undecylmethylcyclotrisiloxane, polydimethylsiloxane and polymethylphenylsiloxane.

[0063] This acne-improving composition may be in any form, including solutions, emulsions, suspensions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactant-containing cleansers, oils, and sprays.

[0064] It can be used as a wash-off cosmetic or a leave-on cosmetic.

[0065] The following is a feasible composition, namely, an acne-removing essence. Weigh out the necessary ingredients for the acne-removing essence according to the table below and prepare the acne-removing essence solution: Serial Number Raw material name W / W (%) 1 rose water 51.20 2 glycerin 15.00 3 Xanthan Gum 0.50 4 Urea 20.00 5 Triacetin (triacetin) 4.00 6 Acylhydroxyxamic acid / 1,2-hexanediol / 1,3-propanediol (1:1:1) 0.80 7 Maltodextrin 6.00 8 Arginine 2.00 9 1% Kava Pepper Extract 0.50 total 100

Claims

1. Application of maltodextrin in the preparation of antibacterial, anti-inflammatory, skin barrier repair, and acne improvement products.

2. The application as described in claim 1, characterized in that: The antibacterial effect described refers to the inhibition of Propionibacterium acnes.

3. The application as described in claim 1, characterized in that: The improvement of acne mentioned includes acne removal, acne treatment, inhibition of acne growth, and inhibition of acne recurrence.

4. The application as described in claim 1, characterized in that: Maltodextrin upregulates the desquamation-related protease KLK7.

5. The application as described in claim 1, characterized in that: The maltodextrin upregulates Caspase-14.

6. The application as described in claim 1, characterized in that: Maltodextrin upregulates desmosome-core protein.

7. The application as described in claim 1, characterized in that: Maltodextrin upregulates desmosome core glycoprotein.

8. A composition for improving acne, characterized in that: Contains maltodextrin; The maltodextrin content in the composition is 0.0001-99.9% by mass.

9. The composition for improving acne as described in claim 8, characterized in that: The composition further comprises a cosmetically acceptable active ingredient, a cosmetically acceptable diluent, or a carrier; The cosmetic's acceptable functional ingredients are selected from at least one of the following: sebum-regulating active substances, antibacterial active substances, oil-controlling active substances, pore-cleansing agents, antioxidants, free radical scavengers, anti-inflammatory agents, tocopherol-like substances, retinol-like substances, soothing active substances, barrier-repairing active substances, blood circulation-promoting active substances, exfoliating active substances, anti-allergy active substances, redness-reducing active substances, whitening agents, moisturizers, cooling agents, abrasives, surfactants, emollients, skin conditioning agents, penetration enhancers, astringents, plant exosomes, and mesenchymal stem cell exosomes. The cosmetic-acceptable diluent or carrier is selected from: (Alkane)diols or triols having 3-10 carbon atoms, preferably selected from glycerol, 1,2-propanediol, 1,3-propanediol, 2-methylpropane-1,3-diol, 1,2-butanediol, 1,3-butanediol, 1,2-pentanediol, 1,3-pentanediol, 1,5-pentanediol, 2,4-pentanediol, 2-methylpentane-2,4-diol, 1,2-hexanediol, 1,6-hexanediol, 1,2-octanediol, dipropylene glycol, preferably 1,2-butanediol, 1,2-pentanediol and / or dipropylene glycol, and / or Esters having 6-36 carbon atoms, preferably monoesters, diesters, or triesters, and preferably selected from diethyl phthalate, diethylhexyl 2,6-naphthalenedicarboxylate, diisopropyl adipate, isopropyl myristate, isopropyl palmitate, isopropyl stearate, isopropyl oleate, n-butyl stearate, n-hexyl laurate, n-decyl oleate, isooctyl stearate, isononyl stearate, isononyl isononanoate, 3,5,5-trimethylhexanoate, and 2-ethylhexyl isononanoate. 2-Ethylhexyl 3,5,5-Trimethylhexanoate, 2-Ethylhexyl 2-Ethylhexanoate, 2-Ethylhexyl palmitate, 2-Ethylhexyl laurate, 2-Hexyldecyl stearate, Cetearyl ethylhexanoate, Stearyl heptanoate, Stearyl octanoate, 2-Octyldodecyl palmitate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, Oleic acid oleate, 2-Ethylhexyl isostearate, Isotridecyl isononanoate, 2-Ethylhexyl cocoate, C benzoate 12-15 - Alkyl esters, cetyl palmitate, triethyl citrate, triacetyl citrate, benzyl benzoate, benzyl acetate, vegetable oils (preferably olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, palm kernel oil) and triglycerides, especially glyceryl stearate, glyceryl triisononanoate, glyceryl laurate, or triglycerides with the same or different CC fatty acid groups (so-called medium-chain triglycerides, caprylic / capric triglycerides such as caprylic triglyceride, capric triglyceride), and / or Branched and unbranched alkyl or alkenyl alcohols, preferably selected from decanol, decenol, octanol, octenol, dodecanool, dodecadienol, octadienol, decadienol, oleyl alcohol, castor oil alcohol, garnet alcohol, stearyl alcohol, isostearyl alcohol, cetyl alcohol, lauryl alcohol, myristyl alcohol, arachidyl alcohol, linoleyl alcohol, linolenic acid alcohol, hexyldecyl alcohol, octyldodecyl alcohol (especially 2-octyl-1-dodecyl alcohol), cetearyl alcohol and behenyl alcohol, and / or Branched and unbranched hydrocarbons and waxes, cyclic or linear silicone oils and dialkyl ethers having 6-24 carbon atoms, preferably selected from jojoba oil, isoeicosane, dioctyl ether, mineral oil, petrolatum, squalane, squalene, cyclopolymethylsiloxane, decamethylcyclopentasiloxane, undecylmethylcyclotrisiloxane, polydimethylsiloxane and polymethylphenylsiloxane.

10. The composition for improving acne as described in claim 8, characterized in that: It can be in any form, including solutions, emulsions, suspensions, pastes, ointments, gels, creams, lotions, powders, soaps, surfactants, oils, and sprays.

Images